Fortis Healthcare Intrinsic Value
Fortis Healthcare (FORTIS) median intrinsic value is ₹286.54 from 10 valuation models (range ₹191–₹478), vs current price ₹955.15 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read FORTIS ex-dividend dates for the complete payout history and dividend yield track record.
FORTIS Valuation Methods Summary — DCF, Graham Number & P/E
Fortis Healthcare intrinsic value across 10 models vs current price ₹955.15 — upside/downside and value range per method. Analyse FORTIS FII DII holdings to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹286.54 | ₹229.23 - ₹343.85 | -70.0% | EPS: ₹14.08, Sector P/E: 12x |
| Book Value Method | asset | ₹191.03 | ₹171.93 - ₹210.13 | -80.0% | Book Value/Share: ₹134.69, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹286.54 | ₹257.89 - ₹315.19 | -70.0% | Revenue/Share: ₹125.83, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹382.06 | ₹343.85 - ₹420.27 | -60.0% | EBITDA: ₹2120.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹382.06 | ₹305.65 - ₹458.47 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹286.54 | ₹257.89 - ₹315.19 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹286.54 | ₹257.89 - ₹315.19 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹477.57 | ₹429.81 - ₹525.33 | -50.0% | ROE: 10.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹286.54 | ₹257.89 - ₹315.19 | -70.0% | EPS: ₹14.08, BVPS: ₹134.69 |
| Dividend Yield Method | dividend | ₹286.54 | ₹257.89 - ₹315.19 | -70.0% | DPS: ₹1.00, Target Yield: 3.5% |
FORTIS Intrinsic Value vs Market Price — All Valuation Models
Fortis Healthcare fair value range ₹191–₹478 vs current market price ₹955.15 across 10 valuation models. For current market price and key ratios, visit Fortis Healthcare share price today.
FORTIS Intrinsic Value Analysis — Undervalued or Overvalued?
Fortis Healthcare median intrinsic value ₹286.54, current price ₹955.15 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of FORTIS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Fortis Healthcare (FORTIS) is ₹286.54 (median value). With the current market price of ₹955.15, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹191.03 to ₹477.57, indicating ₹191.03 - ₹477.57.
Is FORTIS undervalued or overvalued?
Based on our multi-method analysis, Fortis Healthcare (FORTIS) appears to be trading above calculated value by approximately 70.0%.
FORTIS Financial Health — Key Ratios vs Industry Benchmarks
Fortis Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.49 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 10.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 22.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
FORTIS Cash Flow Quality — Operating & Free Cash Flow
Fortis Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,601 Cr | ₹833 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,424 Cr | ₹1,034 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,100 Cr | ₹656 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹822 Cr | ₹636 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹865 Cr | ₹615 Cr | Positive Free Cash Flow | 8/10 |